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The Phox2b gene is necessary for autonomic nervous-system development. Phox2b5/5 mice die in utero with absent
autonomic nervous system circuits, since autonomic nervous system neurons either fail to form or degenerate. We
first identified the Phox2b human ortholog, PHOX2B, as the gene underlying congenital central hypoventilation
syndrome (CCHS, or Ondine curse), with an autosomal dominant mode of inheritance and de novo mutation at
the first generation. We have subsequently shown that heterozygous mutations of PHOX2B may account for several
combined or isolated disorders of autonomic nervous-system development—namely, tumors of the sympathetic
nervous system (TSNS), such as neuroblastoma and late-onset central hypoventilation syndrome. Here, we report
the clinical and molecular assessments of a cohort of 188 probands with CCHS, either isolated or associated with
Hirschsprung disease and/or TSNS. The mutation-detection rate was 92.6% (174/188) in our series, and the most
prevalent mutation was an in-frame duplication leading to an expansion of +5 to +13 alanines in the 20-alanine
stretch at the carboxy terminal of the protein. Such findings suggest PHOX2B mutation screening as a simple and
reliable tool for the diagnosis of CCHS, independent of the clinically variable phenotype. In addition, somatic
mosaicism was detected in 4.5% of parents. Most interestingly, analysis of genotype-phenotype interactions strongly
supports the contention that patients with CCHS who develop malignant TSNS will harbor either a missense or
a frameshift heterozygous mutation of the PHOX2B gene. These data further highlight the link between congenital
malformations and tumor predisposition when a master gene in development is mutated.
Congenital central hypoventilation syndrome (CCHS, or
Ondine curse [MIM 209880]) is a life-threatening dis-
order primarily manifested as sleep-associated respira-
tory insufficiency and markedly impaired ventilatory re-
sponses to hypercarbia and hypoxaemia (Gozal 1998).
Progress in the recognition and clinical management of
patients with CCHS has revealed the presence of broader
structural and functional impairments of the autonomic
nervous system (ANS) (Vanderlaan et al. 2004). In par-
ticular, Hirschsprung disease (HSCR [MIM 142623])
(Croaker et al. 1998) and tumors of autonomic neural
crest derivatives, such as neuroblastoma, ganglioneuro-
blastoma, and ganglioneuroma (Rohrer et al. 2002), are
noted in 20% and 5%–10% of patients with CCHS,
Received November 24, 2004; accepted for publication December
21, 2004; electronically published January 18, 2005.
Address for correspondence and reprints: Dr. Jeanne Amiel, De´par-
tement de Ge´ne´tique, Hoˆpital Necker-Enfants Malades, 149 rue de
Se`vres, 75743 Paris Cedex 15, France. E-mail: amiel@necker.fr
 2005 by The American Society of Human Genetics. All rights reserved.
0002-9297/2005/7603-0006$15.00
respectively. The association of CCHS and HSCR is
known as “Haddad syndrome” (MIM 209880). Finally,
a heterogeneous group of patients with late-onset central
hypoventilation syndrome (LO-CHS) have also been re-
cently described (Katz et al. 2000), although whether
CCHS and LO-CHS should be regarded as the same
entity remains controversial.
In mice, the development of all ANS reflex circuits
is critically dependent on the paired-like homeobox gene
Phox2b (Pattyn et al. 1999; Brunet and Pattyn 2002).
The human PHOX2B gene (MIM 603851) maps on
chromosome 4p12 and encodes a highly conserved 314–
amino-acid homeobox transcription factor with two
short and stable polyalanine repeats of 9 and 20 residues.
(Yokoyama et al. 1999).
On the basis of our initial report indicating a relatively
high frequency of mutations in the human PHOX2B
gene among patients with CCHS, we sought to examine
genotype-phenotype relationships in a large group of
these patients and their families, with particular atten-
tion to the tumoral phenotype. We report on a cor-
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Table 1
Clinical Findings in a Series of 188 Patients with CCHS
PATIENTS







Unknown LO-CHSHSCR HSCRTSNS TSNS
Males 58 21 4 2 6 6 97
Females 62 18 2 2 4 3 91
All 120 39 6 4 10 9 188
relation between the nature of the PHOX2B mutation
and a tumor risk significant enough to allow a focused
follow-up among patients with CCHS.
Patients
Clinical information and blood samples were obtained
with informed consent of the probands or the parents
from a series of 188 patients with CCHS (91 females
and 97 males) and their parents, when possible. Samples
were primarily from the United States, Great Britain,
France, Germany, and Sweden. Twenty-nine patients
have been reported elsewhere (Amiel et al. 2003). Full
detailed clinical data were not available for 10 patients
(5.3%).
The clinical presentations of the 178 remaining pa-
tients are summarized in table 1. With regard to the
ventilatory phenotype, the patients fulfilled the inclu-
sion criteria established in 1999 (Weese-Mayer et al.
1999)—namely, (1) persistent central alveolar hypo-
ventilation (PaCO2 160 mmHg) during sleep, detected
by polysomnography while the patient spontaneously
breathes room air; (2) lack of ventilatory responses to
inhaled CO2; and (3) absence of primary lung, neuro-
muscular, or cardiac disease. HSCR and tumors of the
sympathetic nervous system (TSNS) were observed in
45 (24%) and 10 (5.3%) of the cases, respectively. As
opposed to the distribution of isolated HSCR—in which
the sex ratio is skewed in favor of females, with the
short-segment form of the disease in 80% of the cases
(Croaker et al. 1998)—males and females were equally
affected, and the long-segment form of the disease was
most frequent among cases for which the size of the
aganglionic tract was known (22 cases with long-seg-
ment form, 12 cases with short-segment form, and 11
cases with unknown length of the aganglionic tract).
Cases of TSNS had various degrees of differentiation
and were classified as neuroblastoma (MIM 256700),
ganglioneuroblastoma, or ganglioneuroma in seven,
one, and two cases, respectively; these were either iso-
lated or multifocal (table 1). Finally, our series included
three familial cases: two cases with vertical transmission
of the disease from an affected parent (the father in one
case and the mother in the other case) to his or her child
and one case with recurrence in siblings.
Methods
DNA was extracted in accordance with standard pro-
tocols. We screened the coding sequence of the PHOX2B
gene by denaturing high-pressure liquid chromatogra-
phy and/or direct DNA sequencing, as described else-
where (Amiel et al. 2003). The screening of exon 3 of
the PHOX2B gene was improved by using the protocol
described by Matera et al. (2004). When no mutation
was detected in the PHOX2B coding sequence, we stud-
ied the 533 bp of the promoter region that is known to
be extremely conserved among species and includes pbx-
Hox– and Prep/Meis–binding sites in the mouse (Samad
et al. 2004) (primers available on request). Direct DNA
sequencing was performed by use of the fluorometric
method (Big Dye Terminator Cycle Sequencing kit [Ap-
plied Biosystems]).
Whenever the parental DNA of a CCHS index case
with an identified PHOX2B mutation was available for
study, it was screened by direct DNA sequencing (105
pairs of parents and 19 single parents).
Results
A heterozygous mutation of the PHOX2B gene was
identified in 174 (92.6%) of 188 cases (table 2 and fig.
1). In 161 (92.5%) of the 174 cases with an identifiable
mutation, the mutation consisted of an in-frame dupli-
cation of 15–39 nucleotides, leading to an expansion of
5 to 13 alanines within the 20-alanine tract of the
carboxy terminal of the homeodomain of the protein
(fig. 1). In 10 cases, we identified a small nucleotide
insertion or deletion located 3′ to the homeobox. Such
frameshift mutations presumably resulted in either a
shortened or an elongated protein that may have re-
tained or lost the conserved 20-alanine tract (table 2).
Futhermore, in three of the cases, a missense mutation
in the homeodomain (428ArG [Q143R] or 422GrA
[R141Q]) or in the stop codon (945ArC [X315C]) was
identified. The clinical features presented by these pa-
tients are summarized in table 2. Most of them presented
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Figure 1 PHOX2B mutations among subgroups of patients with
CCHS. The mutation types are reported on the X-axis. Alanine ex-
pansions are symbolized by a plus sign () followed by the number
of extra alanines. MS p missense mutations; FS p frameshift mu-
tations. The minus sign () represents the group of patients (n p
) with no PHOX2B mutation identified. Clinical subgroups are14
listed in the graph key.
Table 2
Patients with CCHS in Whom Heterozygous Missense or Frameshift Mutations of the










O.61   (SS)  (NB) 422GrA 314 (R141Q) P
O.82   (LS)  428ArG 314 (Q143R) P
O.179   (LS)  606–607insA 358 A
S.253    (x NB) 618–619insC 358 A
O.188 ? ? ? 692delG 307 A
O.110   (TCA)  (x NB) 693–700del8 355 A
O.185   ? 689–696dup8 310 A
O.203   (TCA)  722del35 346 A
S.247    (NB) 722del38 345 A
O.123   (LS)  722del38 345 A
O.43    (x NB) 931del5 356 P
O.22   (TCA)  (GGB) 936insT 358 P
O.150   (SS) ? 945ArC 355 P
a  p presence;  p absence; ? p unknown; SS p short-segment HSCR; LS p long-
segment HSCR; TCA p total colonic aganglionosis; NB p neuroblastoma; x p multiple;
GGB p ganglioneuroblastoma.
b 20-alanine stretch in putative protein. Pp present; A p absent.
with HSCR and TSNS (11 and 6 cases, respectively).
Finally, direct sequencing of the PHOX2B coding se-
quence, the intron-exon boundaries, and 530 bp of the
promoter region failed to detect a nucleotide variation
in 14 cases (4 cases of LO-CHS, 7 cases of isolated
CCHS, 2 cases of CCHS  tumor, and 1 case of un-
known presentation). Of the nine previously reported
patients with CCHS in whom no PHOX2B mutation
was identified, seven were found to harbor an in-frame
duplication leading to a polyalanine expansion after
PCR amplification, by use of the protocol described by
Matera et al. (2004).
Regarding familial cases: the vertical transmission of
an alanine expansion (5 and 7 alanines) from an
affected parent to his or her affected child was dem-
onstrated in two cases. In the third familial case, with
recurrence in sibs, we were able to detect paternal so-
matic mosaicism for the mutation that was identified in
the index case (7 alanines). A somatic mosaicism was
detected in 10 cases (6 fathers and 4 mothers). In all
cases, the nucleotide in-frame duplication leading to al-
anine expansion remained unchanged in transmission,
suggesting that such polyalanine expansions are both
meiotically and mitotically stable. These data argue for
unequal allelic homologous recombination as the mu-
tation-causing mechanism, as proposed by Warren
(1997) for alanine expansion in HOXD13.
In the group of patients with LO-CHS (nine cases),
a PHOX2B mutation was found in five cases (fig. 1)
and always consisted of an expansion of 5 alanines.
Neither alanine triplet expansions nor frameshift mu-
tations were found in 250 control chromosomes from
various ethnic backgrounds. Interestingly, 2 of 250 con-
trol alleles exhibited polyalanine contractions—one of
five and the other of seven triplets (not shown).
Discussion
The PHOX2B gene has recently been identified as the
primary gene underlying CCHS, with an autosomal
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dominant mode of inheritance and de novo mutation at
the first generation (Amiel et al. 2003). The PHOX2B
mutation-detection rate is high in CCHS and was ini-
tially underestimated because of major-allele drop-out
(Amiel et al. 2003; Sasaki et al. 2003; Matera et al.
2004). Moreover, the vast majority of the mutations
(161 [92.5%] of 174 cases) are located within the cryptic
triplet region encoding the carboxy terminal stretch of
20 alanines. These observations indicate that PHOX2B
molecular screening may provide a fast and reliable di-
agnostic test in neonates presenting with clinical mani-
festations suggestive of CCHS. The group of patients
with no detectable PHOX2B mutation (14/188) is clin-
ically heterogeneous, although nine patients are not clin-
ically distinguishable from patients with CCHS who
harbor a PHOX2B mutation (fig. 1). Such a small per-
centage of failure to detect the molecular event is not,
per se, a strong argument for genetic heterogeneity.
Somatic mosaicism in one of the parents of a patient
with CCHS was detected in 10 cases by studying
DNA extracted from peripheral leukocytes. This ratio
is unexpectedly high and has direct and important
consequences for genetic counseling. Indeed, although
a recurrence-risk figure cannot be accurately pre-
dicted—since the percentage of germline mosaicism is
unknown—prenatal diagnosis for a future pregnancy
should be proposed, since the recurrence risk may be
as high as 50%. Conversely, it will be of interest to
confirm that somatic mosaicism for a PHOX2B mu-
tation may be detectable in one of the parents of all
cases in which recurrence in siblings has occurred (Had-
dad et al. 1978; Hamilton and Bodurtha 1989; Kerbl
et al. 1996).
Heterozygous PHOX2B mutations were identified in
five of the nine patients with LO-CHS in our series.
Some of these patients are therefore at risk to transmit
either CCHS or LO-CHS to their progeny. It is thus
important to study the PHOX2B gene in all patients
with LO-CHS, so as to provide accurate genetic coun-
seling for these families, even though whether these pa-
tients harbor a germline mutation or a somatic mosa-
icism remains a question. It is interesting to note that,
in contrast to the manifestations of CCHS in humans,
the ventilatory phenotype observed in Phox2b/ mice
(i.e., impaired ventilatory response to inhaled CO2) is
transitory and also less severe than in patients with
CCHS, with the mice showing normal spontaneous
breathing (Dauger et al. 2003). Such discrepant obser-
vations between human and mice argue against hap-
loinsufficiency as the disease-causing mechanism re-
sponsible for the alanine-expansion mutations observed
in humans. Indeed, there is growing evidence for a com-
mon disease-causing mechanism resulting from hetero-
zygous polyalanine expansions—namely, a dominant
negative effect due to cytoplasmic aggregation of both
mutant and wild-type proteins (Albrecht et al. 2004;
Amiel et al. 2004).
Small alanine expansions (range of 5 to 7 ala-
nines) are, by far, the most frequent mutations identified
in our series (fig. 1) and in other series reported to date
(Sasaki et al. 2003; Weese-Mayer et al. 2003; Matera
et al. 2004). Interestingly, the distribution of alanine
expansions differs greatly among the patient subgroups
(fig. 1). Indeed, the smallest alanine expansion was the
only one identified in patients with LO-CHS (5 cases),
whereas it was never found in patients with CCHS 
HSCR (45 patients). Although patients with CCHS 
HSCR tend to harbor a longer alanine expansion, in
comparison with that of patients with isolated CCHS
(fig. 1), one cannot predict the accurate phenotype from
the genotype, since the 7-alanine mutation is the most
frequent expansion in both the group of patients with
isolated CCHS and the group with CCHS  HSCR.
A high predisposition to TSNS has been long rec-
ognized in patients with CCHS (Rohrer et al. 2002).
The incidence of TSNS is indeed 500-fold greater in
these patients than in the general population (5%–10%
vs. 1/10,000 in the general population [Rohrer et al.
2002]). Moreover, when present, the tumors tend to be
multifocal in patients with CCHS. We propose that
such tumor predisposition may be a direct consequence
of the PHOX2B germline heterozygous mutation. In-
deed, such mutations have been identified in both fa-
milial and sporadic cases of neuroblastoma with no
CCHS phenotype (Mosse et al. 2004; Trochet et al.
2004). Interestingly, frameshift and missense PHOX2B
mutations may predispose to neuroblastoma, as op-
posed to mutations leading to polyalanine expansions
(table 2). Indeed, an invasive tumor (neuroblastoma)
was diagnosed in 6 (46%) of 13 patients harboring
either a missense or a frameshift mutation, whereas a
differentiated tumor (ganglioneuroma) was diagnosed
in only 2 (1.24%) of 161 patients harboring an in-frame
duplication leading to an expansion of 9 alanines in
one and 13 in the other. Interestingly, the latter two
patients did not have HSCR. Similar findings in 67 pa-
tients were reported by Weese-Mayer et al. (2003),
whereby a PHOX2B frameshift mutation (K155X) was
found once and in the only patient with CCHS with
neuroblastoma. Matera et al. (2004) also reported three
frameshift mutations in a series of 27 cases, although
the presence of TSNS is not mentioned in this series.
Finally, in the series of 10 patients with CCHS reported
by Sasaki et al. (2003), a PHOX2B frameshift mutation
was found once, in a patient with Haddad syndrome.
In this case, there was no mention of TSNS up to the
age of 4 mo (Sasaki et al. 2003). Thus, PHOX2B mo-
lecular testing points to a subset of patients with CCHS
who are at very high risk for developing tumors and
therefore justify a very careful clinical follow-up, at least
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in the first 2 years of life. Finally, no loss of heterozy-
gosity at the PHOX2B locus was observed in the tumors
of patients with a PHOX2B gene mutation, whenever
it could be tested (Mosse et al. 2004; Trochet et al.
2004). Although we showed that the mutant 931del5
allele was transcriptionally stable, it remains an open
question as to whether frameshift mutations result in
stable and active proteins (Trochet et al. 2004).
In summary, our findings in this extensive series of
patients with CCHS and their families support a major
role for PHOX2B in the generation of normal respi-
ratory patterning and in the normal development of the
ANS in humans. Although modifier genes in both LO-
CHS and Haddad syndrome are likely, PHOX2B is the
major disease-causing gene in CCHS and is a predis-
posing gene to neuroblastoma whenever the mutation
does not result in a polyalanine expansion.
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